Founded in 2016, Moogene is a Republic of Korea INNOPOLIS Foundation spin-off recognized by the Ministry of Science, ICT, and Future Planning (MSIP).
The founding team members began their work at a systems biology laboratory at Harvard Medical School, but the technology has since been independently developed, with clear documentation in top journals such as Nature, Small, Biomaterials, J Nanobiotechnol.
As of June ‘19, Moogene owns over 15% of all CRISPR patents filed from South Korea. Our gene-editing platform technology is being developed for human therapeutics with the backing of investors such as Samsung, Shinhan, and Mirae Asset. Our facilities are in Pangyo Techno Valley, and we have a presence in Boston.